We claim:

1. A pharmaceutical combination comprising a histamine-3 receptor inverse agonist, an acetylcholinesterase inhibitor and a NMDA receptor antagonist; wherein the histamine-3 receptor inverse agonist is selected from the group consisting of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; N-[4-(1-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; and N-[4-(1-Isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; or a pharmaceutically acceptable salt thereof; wherein the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof; and the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

2. The pharmaceutical combination as claimed in claim 1, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof.

3. The pharmaceutical combination as claimed in claim 1, wherein the pharmaceutically acceptable salt of the histamine-3 receptor inverse agonist is selected from the group consisting of
N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride;
N-[4-(1-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate; and
N-[4-(1-Isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate.

4. The pharmaceutical combination as claimed in any one of claims 1 to 3, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride.

5. The pharmaceutical combination as claimed in any one of claims 1 to 4, wherein the acetylcholinesterase inhibitor is donepezil hydrochloride.

6. The pharmaceutical combination as claimed in any one of claims 1 to 5, wherein the NMDA receptor antagonist is memantine hydrochloride.

7. A pharmaceutical combination comprising N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride, donepezil hydrochloride and memantine hydrochloride.

8. The pharmaceutical combination as claimed in any one of claims 1 to 7, for use in therapy.

9. Use of the pharmaceutical combination as claimed in any one of claims 1 to 7, in the manufacture of a medicament for the treatment of a cognitive disorder in a patient.

10. The use as claimed in claim 9, wherein the cognitive disorder is selected from Alzheimer's disease, schizophrenia, Parkinson's disease, Lewy body dementia, vascular dementia, frontotemporal dementia, Down syndrome and Tourette's syndrome.

11. A compound, N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof in a pharmaceutical combination with an acetylcholinesterase inhibitor and a NMDA receptor antagonist for use in therapy; wherein the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof; and the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

12. Use of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of Alzheimer's disease in a patient on stable treatment with an acetylcholinesterase inhibitor and a NMDA receptor antagonist; wherein the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof; and the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

13. The use as claimed in claim 12, wherein 0.1 mg to 100 mg of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

14. The use as claimed in claim 12 or 13, wherein 0.1 mg to 60 mg of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

15. The use as claimed in any one of claims 12 to 14, wherein 0.1 mg to 30 mg of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

16. The use as claimed in any one of claims 12 to 15, wherein 1 mg to 30 mg of donepezil or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

17. The use as claimed in any one of claims 12 to 16, wherein 1 mg to 40 mg of memantine or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

18. A pharmaceutical composition comprising the pharmaceutical combination as claimed in any one of claims 1 to 7, and pharmaceutically acceptable excipients or a combination thereof.

19. The pharmaceutical composition as claimed in claim 18, for use in therapy.

20. Use of the pharmaceutical composition as claimed in claim 18 in the manufacture of a medicament for the treatment of a cognitive disorder selected from the group consisting of Alzheimer’s disease, schizophrenia, Parkinson’s disease, Lewy body dementia, vascular dementia, frontotemporal dementia, Down syndrome and Tourette’s syndrome.

21. The pharmaceutical composition as claimed in claim 18, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof and is present in an amount of 0.1 mg to 100 mg.

22. The pharmaceutical composition as claimed in claim 18 or claim 21, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof and is present in an amount of 0.1 mg to 60 mg.

23. The pharmaceutical composition as claimed in any one of claims 18, 21 and 22, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof and is present in an amount of 0.1 mg to 30 mg.

24. The pharmaceutical composition as claimed in any one of claims 18 and 21 to 23, wherein the acetylcholinesterase inhibitor is present in an amount of 2 mg to 30 mg.

25. The pharmaceutical composition as claimed in any one of claims 18 and 21 to 24, wherein the NMDA receptor antagonist is present in an amount of 1 mg to 40 mg.

26. The use as claimed in claim 12, wherein the N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is to be administered to the patient by oral, nasal, local, dermal or parenteral routes.

27. The use as claimed in claim 12, wherein the N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is to be administered to the patient one to three times per day, one to three times per week or one to three times per month.